Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
SLC-0111 is a selective, small molecule, inhibitor of carbonic anhydrase (CA) IX and is in
development for the treatment of solid tumours over-expressing CA IX. CAIX, a transmembrane
metalloenzyme, is overexpressed on extracellular surfaces of hypoxic tumour cells but its
expression is highly restricted in normal tissue. CAIX is a functional regulator of processes
critical for tumour growth and metastasis, including pH regulation, survival, migration and
invasion.
This prospective single arm study will evaluate the safety of SLC-0111 given once daily in 28
day cycles in subjects with advanced solid tumours. The intent of this research study is to
find our more information such as: the highest dose of SLC-0111 that can be given safely, the
side effect it may cause, to examine how the body affects the study drug concentration in the
blood (pharmacokinetics or PK), and to gain some information on its effectiveness in treating
cancer.